Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants
- Conditions
- Liver Transplantation
- Interventions
- First Posted Date
- 2013-06-27
- Last Posted Date
- 2019-03-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 285
- Registration Number
- NCT01888432
- Locations
- 🇹🇷
Novartis Investigative Site, Mecidiyekoy/Istanbul, Turkey
Standard of Care +/- Midostaurin to Prevent Relapse Post Stem Cell Transplant in Patients With FLT3-ITD Mutated AML
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Other: Standard of Care
- First Posted Date
- 2013-06-21
- Last Posted Date
- 2021-03-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 60
- Registration Number
- NCT01883362
- Locations
- 🇺🇸
University of California at Los Angeles Oncology, Los Angeles, California, United States
🇺🇸Northside Hospital, Atlanta, Georgia, United States
🇺🇸Washington University School Of Medicine-Siteman Cancer Ctr Washington U School of Med, Saint Louis, Missouri, United States
Efficacy and Safety of LCZ696 Compared to Olmesartan in Essential Hypertensive Patients Not Responsive to Olmesartan
- Conditions
- Hypertension
- Interventions
- First Posted Date
- 2013-06-12
- Last Posted Date
- 2015-12-07
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 376
- Registration Number
- NCT01876368
- Locations
- 🇪🇸
Novartis Investigative Site, Madrid, Spain
PK of Serelaxin in Severe Renal Impairment and ESRD
- First Posted Date
- 2013-06-12
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 36
- Registration Number
- NCT01875523
- Locations
- 🇩🇪
Novartis Investigative Site, Grunstadt, Germany
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
- First Posted Date
- 2013-06-11
- Last Posted Date
- 2015-06-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 28
- Registration Number
- NCT01874340
- Locations
- 🇹🇷
Novartis Investigative Site, Atakum / Samsun, Turkey
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 255
- Registration Number
- NCT01872260
- Locations
- 🇺🇸
Univ of California at San Diego Moores Cancer Ctr, San Diego, California, United States
🇺🇸UCSF Medical Center, San Francisco, California, United States
🇺🇸H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
A Study to Evaluate the Effect of LCZ696 on Aortic Stiffness in Subjects With Hypertension
- Conditions
- Hypertension
- Interventions
- Other: placebo to olmesartanOther: placebo to sacubitril/valsartan (LCZ696)
- First Posted Date
- 2013-06-06
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 115
- Registration Number
- NCT01870739
- Locations
- 🇬🇧
Novartis Investigative Site, Glasgow, Scotland, United Kingdom
Vildagliptin/Metformin in T2DM Patients Starting Basal Insulin
- Conditions
- Type 2 Diabetes Mellitus (T2DM)
- Interventions
- First Posted Date
- 2013-06-06
- Last Posted Date
- 2016-04-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 42
- Registration Number
- NCT01871558
- Locations
- 🇫🇷
Novartis Investigative Site, Valenciennes, France
Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF
- First Posted Date
- 2013-06-06
- Last Posted Date
- 2018-03-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 6600
- Registration Number
- NCT01870778
- Locations
- 🇬🇧
Novartis Investigative Site, Swindon, United Kingdom
Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma
- Conditions
- c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM
- Interventions
- Drug: INC280
- First Posted Date
- 2013-06-06
- Last Posted Date
- 2018-05-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 43
- Registration Number
- NCT01870726
- Locations
- 🇺🇸
Dana Farber Cancer Institute SC, Boston, Massachusetts, United States
🇺🇸Columbia University Medical Center- New York Presbyterian Dept of Oncology, New York, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center Neurology, New York, New York, United States